60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Acquires $45,495.21 in Stock

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Geoffrey S. Dow acquired 35,823 shares of the stock in a transaction on Monday, December 9th. The shares were acquired at an average price of $1.27 per share, with a total value of $45,495.21. Following the transaction, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

60 Degrees Pharmaceuticals Stock Up 34.5 %

SXTP stock opened at $1.95 on Wednesday. 60 Degrees Pharmaceuticals, Inc. has a 52 week low of $0.70 and a 52 week high of $18.36. The company has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $0.83. The firm has a market capitalization of $4.48 million, a P/E ratio of -0.19 and a beta of 5.36.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, November 15th.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.